Stock Track | CARsgen Soars 5% as FDA Lifts Clinical Holds on Key Products

Stock Track

Nov 01, 2024

Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.

The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.

CARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1170856402"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170856402\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170856402?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170856402","market":"us","top_or_hot":-1,"title":"Stock Track | CARsgen Soars 5% as FDA Lifts Clinical Holds on Key Products","media":"Stock Track","content":"<p>Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.</p>\n\n<p>The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.</p>\n\n<p>CARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CARsgen Soars 5% as FDA Lifts Clinical Holds on Key Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CARsgen Soars 5% as FDA Lifts Clinical Holds on Key Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-01 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.</p>\n\n<p>The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.</p>\n\n<p>CARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1170856402","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170856402","pubTimestamp":1730424781,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CARsgen Therapeutics Holdings Ltd  surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration  has lifted clinical holds on three of its investigational products.The FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"随着FDA解除关键产品的临床限制，科济生物股价飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"Shares of CARsgen Therapeutics Holdings Ltd (02171) surged over 5% in early trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted clinical holds on three of its investigational products.\nThe FDA has removed the holds on zevorcabtagene autoleucel, satricabtagene autoleucel, and CT071, allowing CARsgen to proceed with clinical trials for these promising cell therapy candidates. Zevorcabtagene autoleucel and satricabtagene autoleucel are CAR-T cell therapies being studied for the treatment of non-Hodgkin's lymphoma, while CT071 is a CAR-T therapy targeting solid tumors.\nCARsgen is a biopharmaceutical company focused on developing innovative cell therapies for cancer and other diseases. The lifting of the FDA clinical holds represents a significant milestone for the company and paves the way for further clinical development of its pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}